ALDH9A1

Across TCGA pan-cancer cohorts, ALDH9A1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ALDH9A1 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ALDH9A1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ALDH9A1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where ALDH9A1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.662	0.392	<.001	81	view →
CCRCC	DFS	Quartile	III,IV	0.788	0.248	.001	42	view →
LUAD	DFS	Median	All	0.878	0.512	.013	13	view →
LSCC	DFS	Tertile	All	0.580	0.852	.021	8	view →
UCEC	DFS	Median	II,III,IV	0.826	1.000	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ALDH9A1–PDAC (OS)

Open the PDAC breakdown →